ADIMMUNE CORPORATION
🇹🇼Taiwan
- Country
- 🇹🇼Taiwan
- Ownership
- -
- Established
- 1965-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.adimmune.com.tw/
Dose-finding Study for AdimrSC-2f Vaccine
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: AdimrSC-2f
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 241
- Registration Number
- NCT05104489
- Locations
- 🇮🇩
University Gadjah Mada Academic Hospital, Yogyakarta, Indonesia
A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: AdimrSC-2f
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 68
- Registration Number
- NCT04522089
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Immunogenicity and Safety Evaluation of QIS in Healthy Subjects
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: AdimFlu-S (QIS)
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 174
- Registration Number
- NCT04101435
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: AdimFlu-V
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT01759654
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: AdimFlu-V
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 122
- Registration Number
- NCT01755364
- Locations
- 🇨🇳
Chang Gung Memorial Hospital at Linkuo, Taoyuan, Taiwan
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza vaccine (split virion, inactivated)Biological: AdimFlu-S
- First Posted Date
- 2012-12-19
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 130
- Registration Number
- NCT01752881
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Pandemic Influenza
- Interventions
- Biological: Pandemic Influenza Vaccine (H5N1)
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 39
- Registration Number
- NCT01640691
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
The Safety and Immune Response to Influenza Vaccination in Pregnant Women
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: AdimFlu-S Influenza Vaccine
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT01514708
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects
Not Applicable
Completed
- Conditions
- Influenza
- Interventions
- Biological: non-elderly aged between 18 and 60Biological: elderly aged over 60
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 128
- Registration Number
- NCT01411358
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: AdimFlu-S Vaccine 2010-2011
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT01356316
© Copyright 2025. All Rights Reserved by MedPath